COYA 301 (Low-dose IL-2)
Autoimmune/Inflammatory (via Treg expansion)
Phase 1Active
Key Facts
Indication
Autoimmune/Inflammatory (via Treg expansion)
Phase
Phase 1
Status
Active
Company
About ARScience Biotherapeutics
ARScience Biotherapeutics is a private, clinical-stage biotech focused on engineering customized interleukins to enhance and modulate immune responses. The company leverages over 20 years of collective team experience in cytokine development and has established a key licensing partnership with Coya Therapeutics for its lead low-dose IL-2 candidate, COYA 301. ARScience aims to partner with cell therapy companies (e.g., CAR-T, NK cells) and pharmaceutical firms to provide cytokine components that improve the efficacy of advanced immunotherapies.
View full company profile